Get the Stockscreener App
8.25
5.06%
-0.44
After Hours:
8.41
0.16
+1.94%
Sagimet Biosciences Inc stock is traded at $8.25, with a volume of 826.73K.
It is down -5.06% in the last 24 hours and up +2.74% over the past month.
Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.
See More
Previous Close:
$8.69
Open:
$8.6
24h Volume:
826.73K
Relative Volume:
0.56
Market Cap:
$253.07M
Revenue:
-
Net Income/Loss:
$-29.25M
P/E Ratio:
-6.9562
EPS:
-1.186
Net Cash Flow:
$-22.80M
1W Performance:
-19.43%
1M Performance:
+2.74%
6M Performance:
+87.50%
1Y Performance:
+137.07%
1-Day Range:
$7.98
$8.81
1-Week Range:
$7.98
$10.46
52-Week Range:
$1.73
$11.41
Sagimet Biosciences Inc Stock (SGMT) Company Profile
Name
Sagimet Biosciences Inc
Sector
Industry
Phone
(650) 561-8600
Address
155 BOVET RD., SUITE 303, SAN MATEO
Compare SGMT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SGMT
Sagimet Biosciences Inc
|
8.25 | 279.78M | 0 | -29.25M | -22.80M | -1.186 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.13 | 117.32B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.87 | 58.89B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
401.80 | 51.14B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
673.80 | 41.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
299.01 | 32.59B | 3.81B | -644.79M | -669.77M | -6.24 |
Sagimet Biosciences Inc Stock (SGMT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-24-25 | Initiated | Canaccord Genuity | Buy |
| Dec-06-24 | Initiated | Oppenheimer | Outperform |
| Nov-12-24 | Initiated | UBS | Buy |
| Jun-28-24 | Downgrade | Goldman | Buy → Neutral |
| May-02-24 | Initiated | H.C. Wainwright | Buy |
| Mar-25-24 | Initiated | Leerink Partners | Outperform |
| Aug-08-23 | Initiated | Goldman | Buy |
| Aug-08-23 | Initiated | JMP Securities | Mkt Outperform |
| Aug-08-23 | Initiated | Piper Sandler | Overweight |
| Aug-08-23 | Initiated | TD Cowen | Outperform |
View All
Sagimet Biosciences Inc Stock (SGMT) Latest News
How does Sagimet Biosciences Inc. compare to its industry peersBuild wealth faster with consistent investment plans - jammulinksnews.com
What are the technical indicators suggesting about Sagimet Biosciences Inc.Free Stock Outlook That Work - jammulinksnews.com
Wyckoff Accumulation Phase Possible in Sagimet Biosciences Inc.Entry Alert Based on Volume Spikes Detected - metal.it
Is it the right time to buy Sagimet Biosciences Inc. stockStock Strategy Entry Points Backed By Experts - jammulinksnews.com
What makes Sagimet Biosciences Inc. stock price move sharplyMarket Forecast Alerts Backed By Experts - jammulinksnews.com
What are the latest earnings results for Sagimet Biosciences Inc.Swing Trade Updates To Watch Now - jammulinksnews.com
Can Sagimet Biosciences Inc. hit a new high this monthTrade Setups With Clear Risk Limits Highlighted - metal.it
Why Sagimet Biosciences Inc. stock attracts strong analyst attentionEntry Alert With Low Drawdown Strategy Noted - beatles.ru
Sagimet Biosciences Inc. Stock Performance After Earnings: Historical InsightsWeekly Portfolio Update with ROI Focus - Newser
Risk adjusted return profile for Sagimet Biosciences Inc. analyzedFree Alert Feed for Momentum Based Picks - Newser
How high can Sagimet Biosciences Inc. stock price go in 2025Daily Stock Forecast Powered by AI Tools - Newser
How Sagimet Biosciences Inc. stock performs during market volatilityCommunity Strategy With High Win Rate Backtested - metal.it
Custom watchlist performance reports with Sagimet Biosciences Inc.Secure Asset Flow and Trend Pattern Analysis - Newser
Sagimet Biosciences Inc. Enters Reversal Setup in Weekly ChartsLow Volatility Stable Growth Picks Rank High - metal.it
Is Sagimet Biosciences Inc. stock reversal real or fakeMulti-Year Signal Summary and Entry Timing - Newser
Chart Patterns Forming a Bullish Setup in Sagimet Biosciences Inc.Investment Plan With Growth Optimization Finalized - metal.it
Sagimet Biosciences Inc. (NASDAQ:SGMT) Receives $26.83 Consensus Target Price from Brokerages - Defense World
Published on: 2025-07-29 07:13:29 - metal.it
How Efficient Is Sagimet Biosciences Inc. at Controlling Operating CostsRisk Limited High Gain Trades - beatles.ru
Sagimet Biosciences Inc. Company Revenue and Profit Trends: A Deep Dive Strategy Playbook for Risk Controlled Trades - Newser
Sagimet Biosciences (NASDAQ:SGMT) Now Covered by Analysts at Canaccord Genuity Group - MarketBeat
Reviewing Sagimet Biosciences (NASDAQ:SGMT) & Eledon Pharmaceuticals (NASDAQ:ELDN) - Defense World
What are analysts’ price targets for Sagimet Biosciences Inc. in the next 12 monthsFinancial News Trend Scanner For Every Investor - jammulinksnews.com
Should I hold or sell Sagimet Biosciences Inc. stock in 2025Consistent triple-digit returns - jammulinksnews.com
What catalysts could drive Sagimet Biosciences Inc. stock higher in 2025Gain insights from top financial experts - jammulinksnews.com
Sagimet Biosciences Inc. Company Revenue and Profit Trends: A Deep DiveSteady Profit Stock Forecasts - Newser
Sagimet Biosciences (NASDAQ:SGMT) Earns Buy Rating from Analysts at Canaccord Genuity Group - Defense World
Sagimet Biosciences Bets Big On First-In-Class Fatty Acid Blockers - Finimize
What analysts say about Sagimet Biosciences Inc. stockPhenomenal wealth increase - PrintWeekIndia
Sagimet Biosciences Inc (SGMT) Stock: Navigating a Year of Volatility - investchronicle.com
Strategic Catalysts and Valuation Upside in Sagimet Biosciences (SGMT): A M&A-Driven Biotech Play - AInvest
Sagimet stock gains as Canaccord starts with Buy (SGMT:NASDAQ) - Seeking Alpha
This Sarepta Therapeutics Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Thursday - Benzinga
Canaccord Genuity initiates Sagimet Biosciences coverage with a Buy rating, $28 PT. - AInvest
Sagimet Biosciences Inc. Stock Analysis and ForecastBreakthrough capital growth - Autocar Professional
Sagimet Biosciences Inc Stock (SGMT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):